Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2024 09:45 ET | Source: Kairos Pharma, Ltd.

Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer

LOS ANGELES, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune...
July 06, 2022 07:12 ET | Source: Zenith Capital Corp.

Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials

CALGARY, Alberta, July 06, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI...
February 01, 2022 06:30 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™...
November 02, 2021 07:00 ET | Source: Nanospectra Biosciences, Inc.

Nanospectra Biosciences Announces Enrollment Completion of Pivotal Study of AuroLase Therapy for Ablation of Prostate Tissue

HOUSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective photothermal ablation, today announced the...
September 21, 2021 08:00 ET | Source: Zenith Capital Corp.

Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study

CALGARY, Alberta, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) and Newsoara BioPharma Co., Ltd. (“Newsoara”) announced today the initiation of a...
February 05, 2019 03:22 ET | Source: Druggability Technologies Holdings Ltd

DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development

NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies USA today announced the expansion of the clinical team, with the addition of Dr. Elizabeth Manning Duus, who has been named...